Such a correlation was also observed in NAFLD patients where SLC13A5 expression was 2-fold higher in patients with plasmid IL-6 levels above 4.81 pg/mL compared with patients with IL-6 below this cutoff line. Here, SLC13A5 is linked to metabolic dysfunction-associated steatotic liver disease.